ReviewCurrent opinion in endocrinology, diabetes, and obesity2016
Novel treatment strategies in congenital adrenal hyperplasia.
Review in Current opinion in endocrinology, diabetes, and obesity, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Pooled it
- 24-Hour Profiles of 11-Oxygenated CFrontiers in endocrinology · 2021Trial
- Clinical burden of classic congenital adrenal hyperplasia and glucocorticoid-related complications: a claims analysis.Journal of the Endocrine Society · 2026Article
- Treatment and Follow-up of Congenital Adrenal Hyperplasia Due to 21-hydroxylase Deficiency in Childhood and AdolescenceJournal of clinical research in pediatric endocrinology · 2025Review
- Non-classical animal models for studying adrenal diseases: advantages, limitations, and implications for research.Laboratory animal research · 2024Review
- Bone mineral density determinants in adolescents and young adults with congenital adrenal hyperplasia.Frontiers in pediatrics · 2024Article
- Crinecerfont, a CRF1 Receptor Antagonist, Lowers Adrenal Androgens in Adolescents With Congenital Adrenal Hyperplasia.The Journal of clinical endocrinology and metabolism · 2023Article
- Cardiometabolic Health in Adolescents and Young Adults with Congenital Adrenal Hyperplasia.Medicina (Kaunas, Lithuania) · 2022Article
- Congenital Adrenal Hyperplasia-Current Insights in Pathophysiology, Diagnostics, and Management.Endocrine reviews · 2022Review
- [Gene and cell therapy of adrenal pathology: achievements and prospects].Problemy endokrinologii · 2021Review
- Hydrocortisone dosing in children with classic congenital adrenal hyperplasia: results of the German/Austrian registry.Endocrine connections · 2021Article
- Behavioral assessment of females with congenital adrenal hyperplasia.Hormones (Athens, Greece) · 2021Article
- Masculinized Second-to-Fourth Digit Ratio (2D:4D Ratio) Is Associated With Lower Cortisol Response in Infant Female Rhesus Monkeys (Frontiers in behavioral neuroscience · 2020Article
- Assisted Reproduction in Congenital Adrenal Hyperplasia.Frontiers in endocrinology · 2019Review
- Latest Insights on the Etiology and Management of Primary Adrenal Insufficiency in Children.Journal of clinical research in pediatric endocrinology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
purpose of reviewIn recent years, important steps have been taken to improve the treatment of congenital adrenal hyperplasia (CAH), a relatively stagnant area for decades. In this review, we summarize these advances and propose future lines of investigation. RECENT
findingsThe two main goals of CAH treatment are to replace the deficient hormones when necessary and to dampen the adrenocorticotropin activation and the ensuing adrenal androgen excess. Glucocorticoids have been the mainstay of CAH treatment, but available preparations only partially meet the clinical needs. Recent efforts have focused on improving the delivery of glucocorticoid replacement agents, to closer mimic the physiologic secretion pattern. Examples include modified release oral glucocorticoids and continuous subcutaneous hydrocortisone pumps. Furthermore, nonglucocorticoid approaches to address the androgen excess have emerged, such as inhibition of key androgenic enzymes and adrenocorticotropin secretion blockade by corticotropin-releasing hormone receptor antagonists. SUMMARY: The promising recent progress made in CAH treatment brings new perspectives for individualized care in this complex disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.